Gene Therapy For Ocular Rare Disease Pipeline, Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies- Gamut Therapeutics

Gene Therapy For Ocular Rare Disease Pipeline, Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies- Gamut Therapeutics
(Nevada, Las Vegas) United States DelveInsight's "Gene Therapy For Ocular Rare Disease Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Gene Therapy For Ocular Rare Disease market. A detailed picture of the Gene Therapy For Ocular Rare Disease pipeline landscape is provided, which includes the disease overview and Gene Therapy For Ocular Rare Disease treatment guidelines.

Download the sample page @ https://www.delveinsight.com/sample-request/gene-therapy-for-ocular-rare-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Key Takeaways from the Gene Therapy For Ocular Rare Disease Pipeline Report
Leading Gene Therapy For Ocular Rare Disease companies developing novel drug candidates for improvement include Gamut Therapeutics and many others
Promising Whim Syndrome Areata pipeline therapies in various stages of development include Luxturna and many others

Gene Therapy For Ocular Rare Disease Overview
Gene therapy is a medical technology that aims to produce a therapeutic effect through the manipulation of gene expression or through altering the biological properties of living cells.

The first attempt at modifying human DNA was performed in 1980, by Martin Cline, but the first successful nuclear gene transfer in humans, approved by the National Institutes of Health, was performed in May 1989. The first therapeutic use of gene transfer as well as the first direct insertion of human DNA into the nuclear genome was performed by French Anderson in a trial starting in September 1990

Discover more about the emerging drugs Gene Therapy For Ocular Rare Disease Treatment Drugs @ https://www.delveinsight.com/report-store/gene-therapy-for-ocular-rare-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Gene Therapy For Ocular Rare Disease Pipeline Therapies and Key Companies
Deuruxolitinib: Concert Pharmaceuticals
EQ101: Equillium
MAX 40070: Maxinovel Pharmaceuticals
And many others

Gene Therapy For Ocular Rare Disease Pipeline Therapeutics Assessment
DelveInsight's Report covers around 20+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates
Gene Therapy For Ocular Rare Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

Scope of the Gene Therapy For Ocular Rare Disease Pipeline Report
Coverage: Global
Key Gene Therapy For Ocular Rare Disease Companies: Concert Pharmaceutical, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited, and others
Key Gene Therapy For Ocular Rare Disease Pipeline Therapies: Deuruxolitinib, EQ101, MAX 40070, and others.
Find out more about the treatment options in development Gene Therapy For Ocular Rare Disease Clinical Trials @ https://www.delveinsight.com/report-store/gene-therapy-for-ocular-rare-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight

Adya Kaul
info@delveinsight.com
+1(919)321-6187

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

This release was published on openPR.